[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay].
A chemosensitivity test for UFT and FT-207, which are used in long-term administration clinically, was investigated for prediction of clinical response. Five transplantation-established human tumor xenograft systems were examined using subrenal capsule assay. Both anticancer agents showed antiproliferative effects according to the total administered dose. Two of 5 tumors were determined to be sensitive to UFT using microscopic measurements following intragastric administration of 1/2 of the LD50 value, while they were shown to be resistant to 5-FU. In these two cases, prolongation of life span by long-term administration of UFT was shown clinically. All these experiments could be performed on condition that the loss of body weight in mice was less than 20%. These results suggest that in the 4-day subrenal capsule assay, clinical responses to long-term administration of UFT or FT-207 are predictable using intragastric high-dose administration which does not induce more than 20% body weight loss in experimental mice.
D000230:Adenocarcinoma / Q000473:pathology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003110:Colonic Neoplasms / Q000473:pathology; D003114:Colony-Forming Units Assay; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D013274:Stomach Neoplasms / Q000473:pathology; D005641:Tegafur / Q000494:pharmacology*; D014410:Tumor Stem Cell Assay; D014498:Uracil / Q000494:pharmacology
D005641:Tegafur; D014498:Uracil